Analyzes circadian rhythm gene expressions in organic erectile dysfunction, suggesting novel therapeutic targets.
INTRODUCTION: Despite advances in understanding the vascular basis of erectile dysfunction (ED), the cellular heterogeneity and gene regulatory dynamics underlying organic ED remain unclear. In this study, we characterize the cell type-specific expression and roles of circadian rhythm genes (CRGs) in the human corpus cavernosum affected by organic ED. METHODS: We performed an integrative single-cell analysis of human corpus cavernosum tissues (GSE206528) from healthy controls and patients with organic ED. Cell identities were annotated using Seurat, followed by pseudotemporal trajectory inference with Monocle 2, intercellular communication profiling via CellChat, and quantification of circadian rhythm gene activity using AUCell. Candidate therapeutics targeting dysregulated circadian genes were prioritized through Enrichr-based drug enrichment analysis and evaluated by AutoDock 4-mediated molecular docking. RESULTS: Single-cell RNA-seq analysis of the corpus cavernosum in organic ED revealed reduced fibroblasts and expanded pericytes. The identified core circadian genes (PER1, BHLHE40, NFIL3, KLF10) displayed stage-specific pseudotime dynamics: monotonic decline in endothelial cells versus early-peak decay in fibroblasts, and correlated with pathological crosstalk, including TGF-β/ECM-mediated fibroblast-vascular interactions and enhanced endothelial-immune adhesion. NFIL3 harbored a conserved druggable pocket, and in silico docking confirmed stable binding of repurposable clinical compounds, highlighting circadian targets for therapy. DISCUSSION: This study utilized single-cell RNA sequencing to elucidate the cellular and molecular landscape of the corpus cavernosum in patients with organic ED. The findings revealed significant alterations in cellular composition, circadian gene regulation, and intercellular communication networks. CONCLUSION: Our research characterized circadian rhythm dysregulation as an active, cell type-specific contributor to organic ED and identified NFIL3 as a promising druggable target for chronotherapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: